Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $185.61M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 1.58M
Average 0.22M
PRE Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Prenetics Global LimitedNASDAQ: PRE
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $35.95M rose 107.7% year over year, behind the +174.0% change in trailing-twelve-month revenue. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +91.5% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $224.11M (+142.6%) for the fiscal year ending Dec 2026, a slowdown from the +201.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $35.95M-1.7% QoQ
- Last fiscal yearDec 2025
- $92.39M+201.7% YoY
- LTMMar 2026
- $113.75M+174.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +107.7% | +182.0% | +74.3 pp |
| 1 year | +201.7% | +142.6% | -59.2 pp |
| 3-year CAGR | +91.5% | +79.2% | -12.2 pp |
| 5-year CAGR | +53.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 92.39M USD
- Year-over-year change
- +201.7%
- 4-year CAGR
- +64.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.39M | +201.7% |
| FY2024 | 2024-12-31 | 30.62M | +40.8% |
| FY2023 | 2023-12-31 | 21.74M | +65.2% |
| FY2022 | 2022-12-31 | 13.16M | +5.0% |
| FY2021 | 2021-12-31 | 12.53M | — |
Revenue vs competitors
How PRE compares with its peers on the latest reported figures
- PRE's LTM Mar 2026 revenue of $113.75M is the 3rd highest of the 11 companies compared; the peer median is $39.72M.
- Its year-over-year change of +174.0% is the highest of 11, against a peer median of -7.9%.
- Over three fiscal years its annual growth of +91.5% compares with a peer median of -2.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
ATLNAtlantic International Corp. | LTM Dec 2025 | $435.88M | -1.5% | -0.4% |
| LTM Mar 2026 | $151.64M | +69.5% | +31.8% | |
| LTM Mar 2026 | $113.75M | +174.0% | +91.5% | |
| LTM Mar 2026 | $113.02M | -30.1% | -33.3% | |
| LTM Mar 2026 | $78.09M | +56.8% | -20.2% | |
| LTM Mar 2026 | $44.88M | +39.6% | +53.9% | |
| LTM Mar 2026 | $34.56M | -45.8% | -29.2% | |
| LTM Mar 2026 | $32.29M | -14.3% | -9.3% | |
| LTM Mar 2026 | $18.87M | +34.8% | +34.8% | |
| LTM Mar 2026 | $2.96M | -37.1% | -3.8% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $1.95M | -49.3% | +61.8% |
| Peer median (excluding PRE) | $39.72M | -7.9% | -2.1% | |
Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.53M | 13.16M | 21.74M | 30.62M | 92.39M |
| Cost of Revenue | 8.93M | 9.55M | 12.91M | 15.22M | 43.6M |
| Gross Profit | 3.6M | 3.62M | 8.83M | 15.4M | 48.79M |
| Gross Margin | 28.7% | 27.5% | 40.6% | 50.3% | 52.8% |
| Research & Development | 6.39M | 5.99M | 11.66M | 10.92M | 5.13M |
| Selling, General & Admin | 53.67M | 64.08M | 49.68M | 55.37M | 79.8M |
| Operating Expenses | 60.26M | 69.64M | 60.74M | 63.54M | 86.92M |
| Depreciation & Amortization | 7.35M | 7.54M | 7.79M | 5.93M | 3.78M |
| EBITDA | (209.16M) | (218.04M) | (47.9M) | (51.57M) | (32.19M) |
| EBITDA Margin | -1668.9% | -1656.3% | -220.3% | -168.4% | -34.8% |
| Operating Income | (56.66M) | (66.02M) | (51.91M) | (48.14M) | (38.13M) |
| Operating Margin | -452.1% | -501.5% | -238.7% | -157.2% | -41.3% |
| Interest Income | 201 | 472K | 3.92M | 2.04M | 1.04M |
| Interest Expense | 42.23K | 242K | 119.66K | 203K | 241K |
| Other Income / Expenses | (159.89M) | (159.8M) | (4.76M) | (9.56M) | 1.92M |
| Income Before Tax | (216.55M) | (225.82M) | (56.67M) | (57.7M) | (36.21M) |
| Pre-Tax Margin | -1727.9% | -1715.4% | -260.6% | -188.4% | -39.2% |
| Income Tax Expense | 2.57M | (245K) | (269.36K) | (7.87M) | 34K |
| Net Income | (174.01M) | (190.45M) | (62.72M) | (46.3M) | (37.71M) |
| Net Margin | -1388.4% | -1446.8% | -288.5% | -151.2% | -40.8% |
| EPS (Basic) | (47.04) | (37.57) | (5.58) | (3.64) | (2.68) |
| EPS (Diluted) | (47.04) | (37.57) | (5.58) | (3.64) | (2.68) |
| Weighted Avg Shares | 3.7M | 5.07M | 11.25M | 12.71M | 14.05M |
| Weighted Avg Shares (Diluted) | 3.7M | 5.07M | 11.25M | 12.71M | 14.05M |
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.